NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Dogwood Therapeutics, Inc. (DWTX) Stock Analysis

Dogwood Therapeutics, Inc. (DWTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DWTX

$2.29

−$0.07 (−2.97%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DWTX with… →

DWTX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.37
Previous Close
$2.36
Day's Range
2.25–2.38
52-Week Range
1.28–9.50
Volume
70.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.83
Valuation
Market Cap
$77.84M
P/E Ratio
1.21
EPS (ttm)Profit attributable to each share over the last twelve months.
1.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.26M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.99M
1-Year Return
−54.20%
Dividend and dates
Avg Volume
80.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DWTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.95%
2025+67.07%
2024−82.68%
2023+143.64%
2022−95.39%
2021−31.89%
2020 (partial year)−55.06%

As of September 4, 2026.

DWTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.26M—
2024$0.00−$12.35M—
2023$0.00−$5.30M—
2022$0.00−$12.25M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$27.97M−$34.26M—
2024$0.00—−$12.23M−$12.35M—
2023$0.00—−$5.45M−$5.30M—
2022$0.00—−$12.32M−$12.25M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DWTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricDWTXBiotechnology medianvs median
P/E1.2112.570.1x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Dogwood Therapeutics, Inc. (DWTX) at $77.84M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

Over the past 52 weeks the price has ranged from $1.28 to $9.50. The most recent close on file for DWTX is $2.29, dated September 4, 2026. That is −$0.07 (−2.97%) against the previous close. The latest close sits 78.91% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $34.26M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 1.89.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 1.21. That is 0.1 times the Biotechnology median of 12.57. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.83. Daily returns over the trailing 5 years annualize to a volatility of 218.57%. The trailing one-year price return is −54.20%. Measured over 5 years, that is −56.20% a year compounded.

Growth & Income

The record shows no dividend for DWTX.

2026 is still running; the price is −44.95% year to date. Across the complete calendar years on file, 2023 returned +143.64% and 2022 returned −95.39%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Dogwood Therapeutics, Inc. (DWTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dogwood Therapeutics, Inc. DWTX $77.84M 1.2
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Dogwood Therapeutics, Inc. trades at a P/E of 1.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Visit website →